Showing results (1091-1100 of 1,274) with videos related to
Sort By:
Pageof 128
The Journal of Nutrition|October 16, 2015
Addressing Current Criticism Regarding the Value of Self-Report Dietary DataAmy F Subar, Laurence S Freedman, Janet A Tooze, et al.Journal of Neurology|November 16, 2007
Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1bChris Polman, Ludwig Kappos, Mark S Freedman, et al.The Lancet. Neurology|November 23, 2020
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trialBruce A C Cree, Gary Cutter, Jerry S Wolinsky, et al.Lancet (London, England)|July 2, 2002
Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over studySaroj Vadhan-Raj, John J Kavanagh, Ralph S Freedman, et al.The Lancet. Neurology|September 15, 2009
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trialLudwig Kappos, Mark S Freedman, Chris H Polman, et al.Epidemiology (Cambridge, Mass.)|January 4, 2001
Cancer registration in the Middle EastL S Freedman, S Al-Kayed, M B Qasem, et al.Plos One|March 20, 2010
Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza A(H1N1) diseaseOliver W Morgan, Anna Bramley, Ashley Fowlkes, et al.Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|September 30, 2022
Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022Noam Barda, Michal Canetti, Mayan Gilboa, et al.Oncogene|October 6, 2009
Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi originI Wolf, Y Laitman, T Rubinek, et al.Leukemia & Lymphoma|July 12, 2014
Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphomaEric Jacobsen, Olga Pozdnyakova, Robert Redd, et al.Pageof 128